CN118236338B - Preparation method of voronoi fumarate preparation - Google Patents
Preparation method of voronoi fumarate preparation Download PDFInfo
- Publication number
- CN118236338B CN118236338B CN202410675348.4A CN202410675348A CN118236338B CN 118236338 B CN118236338 B CN 118236338B CN 202410675348 A CN202410675348 A CN 202410675348A CN 118236338 B CN118236338 B CN 118236338B
- Authority
- CN
- China
- Prior art keywords
- preparation
- nuola
- raw
- fumaric acid
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 175
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 title claims abstract description 84
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 239000003826 tablet Substances 0.000 claims abstract description 150
- 239000003814 drug Substances 0.000 claims abstract description 95
- 150000007524 organic acids Chemical class 0.000 claims abstract description 72
- 239000007788 liquid Substances 0.000 claims abstract description 63
- 238000002156 mixing Methods 0.000 claims abstract description 36
- 238000005469 granulation Methods 0.000 claims abstract description 31
- 230000003179 granulation Effects 0.000 claims abstract description 31
- 239000000853 adhesive Substances 0.000 claims abstract description 27
- 230000001070 adhesive effect Effects 0.000 claims abstract description 27
- 239000007941 film coated tablet Substances 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- -1 one-step granulation Substances 0.000 claims abstract 2
- 238000000576 coating method Methods 0.000 claims description 167
- 239000011248 coating agent Substances 0.000 claims description 151
- 239000002994 raw material Substances 0.000 claims description 82
- 229940079593 drug Drugs 0.000 claims description 80
- 239000000463 material Substances 0.000 claims description 79
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 65
- 239000008213 purified water Substances 0.000 claims description 61
- 229960003022 amoxicillin Drugs 0.000 claims description 55
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 55
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 55
- 239000008187 granular material Substances 0.000 claims description 44
- 239000007888 film coating Substances 0.000 claims description 40
- 238000009501 film coating Methods 0.000 claims description 40
- 239000001530 fumaric acid Substances 0.000 claims description 38
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 34
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 34
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 34
- 238000003756 stirring Methods 0.000 claims description 33
- 239000007787 solid Substances 0.000 claims description 26
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 20
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 20
- 239000002245 particle Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 14
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 14
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 14
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 14
- 239000006185 dispersion Substances 0.000 claims description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 229960003943 hypromellose Drugs 0.000 claims description 12
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 10
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 10
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 10
- 239000004408 titanium dioxide Substances 0.000 claims description 10
- 239000001069 triethyl citrate Substances 0.000 claims description 10
- 235000013769 triethyl citrate Nutrition 0.000 claims description 10
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 10
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 239000003086 colorant Substances 0.000 claims description 7
- 239000004014 plasticizer Substances 0.000 claims description 7
- 239000000945 filler Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 229940069328 povidone Drugs 0.000 claims description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000003605 opacifier Substances 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008016 pharmaceutical coating Substances 0.000 claims 1
- 235000015424 sodium Nutrition 0.000 claims 1
- 229940083542 sodium Drugs 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 22
- 108010036781 Fumarate Hydratase Proteins 0.000 abstract 2
- 102100036160 Fumarate hydratase, mitochondrial Human genes 0.000 abstract 2
- 230000000873 masking effect Effects 0.000 abstract 1
- 229950003825 vonoprazan Drugs 0.000 description 105
- ROGSHYHKHPCCJW-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-n-methylmethanamine Chemical compound OC(=O)\C=C\C(O)=O.C=1C=CN=CC=1S(=O)(=O)N1C=C(CNC)C=C1C1=CC=CC=C1F ROGSHYHKHPCCJW-WLHGVMLRSA-N 0.000 description 104
- 239000000243 solution Substances 0.000 description 87
- 238000000889 atomisation Methods 0.000 description 24
- 230000002572 peristaltic effect Effects 0.000 description 24
- 239000007921 spray Substances 0.000 description 24
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 15
- 238000009475 tablet pressing Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 238000013112 stability test Methods 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000590002 Helicobacter pylori Species 0.000 description 6
- 229940037467 helicobacter pylori Drugs 0.000 description 6
- MQXQVCLAUDMCEF-CWLIKTDRSA-N amoxicillin trihydrate Chemical compound O.O.O.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 MQXQVCLAUDMCEF-CWLIKTDRSA-N 0.000 description 5
- 238000007922 dissolution test Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011978 dissolution method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229960002626 clarithromycin Drugs 0.000 description 3
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 230000027119 gastric acid secretion Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000516 sunscreening agent Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 101001121408 Homo sapiens L-amino-acid oxidase Proteins 0.000 description 2
- 102100026388 L-amino-acid oxidase Human genes 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- 101100012902 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FIG2 gene Proteins 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 239000008358 core component Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 101100233916 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR5 gene Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- NAYRZLVSOLIQSH-UHFFFAOYSA-N acetonitrile;methanol;phosphoric acid Chemical compound OC.CC#N.OP(O)(O)=O NAYRZLVSOLIQSH-UHFFFAOYSA-N 0.000 description 1
- FGDQGIKMWOAFIK-UHFFFAOYSA-N acetonitrile;phosphoric acid Chemical compound CC#N.OP(O)(O)=O FGDQGIKMWOAFIK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001914 gastric parietal cell Anatomy 0.000 description 1
- 239000011361 granulated particle Substances 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- LJSOLTRJEQZSHV-UHFFFAOYSA-L potassium;sodium;hydron;hydroxide;phosphate Chemical compound [OH-].[Na+].[K+].OP(O)([O-])=O LJSOLTRJEQZSHV-UHFFFAOYSA-L 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- BFDBKMOZYNOTPK-UHFFFAOYSA-N vonoprazan Chemical compound C=1C=CN=CC=1S(=O)(=O)N1C=C(CNC)C=C1C1=CC=CC=C1F BFDBKMOZYNOTPK-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
技术领域Technical Field
本发明涉及富马酸伏诺拉生制剂制备技术领域,具体涉及一种富马酸伏诺拉生制剂的制备方法。The invention relates to the technical field of preparation of vonoprazan fumarate preparations, and in particular to a preparation method of vonoprazan fumarate preparations.
背景技术Background Art
富马酸伏诺拉生是一种新型的钾离子竞争性酸阻滞剂(P-CAB),能够在胃壁细胞胃酸分泌的最后一环中,通过抑制K+对H+-K+-ATP酶(质子泵)的结合作用,提前终止胃酸的分泌,具有强大、持久的抑制胃酸分泌作用,具有首剂全效、药效持久、服用方便等特点,在治疗胃食管反流性疾病(GERD)、协同抗生素根除幽门螺杆菌(Hp)、治疗幽门螺杆菌的消化性溃疡等疾病时有确切的疗效,不良反应少、有更好的安全性和耐受性。Vonoprazan fumarate is a new type of potassium ion competitive acid blocker (P-CAB) that can terminate gastric acid secretion prematurely in the last link of gastric acid secretion in gastric parietal cells by inhibiting the binding of K + to H + -K + -ATPase (proton pump). It has a strong and lasting effect in inhibiting gastric acid secretion, and has the characteristics of full effect in the first dose, long-lasting efficacy, and easy to take. It has definite therapeutic effects in the treatment of gastroesophageal reflux disease (GERD), synergistic antibiotics to eradicate Helicobacter pylori (Hp), and treatment of Helicobacter pylori-induced peptic ulcers. It has few adverse reactions and better safety and tolerability.
幽门螺杆菌存在于人类的口腔、胃和十二指肠,是引起胃炎、胃癌、胃及十二指肠溃疡的重要病因,且具有传染性。目前针对幽门螺杆菌感染常用的治疗方法为三联疗法,即一种质子泵抑制剂加两种抗生素,抗生素多是阿莫西林、克拉霉素等。由于富马酸伏诺拉生与克拉霉素的代谢酶均为CYP3A4,这两种药物会互相抑制代谢,导致富马酸伏诺拉生的血药浓度升高。Helicobacter pylori exists in the human mouth, stomach and duodenum. It is an important cause of gastritis, gastric cancer, gastric and duodenal ulcers, and is contagious. Currently, the commonly used treatment for Helicobacter pylori infection is triple therapy, which is a proton pump inhibitor plus two antibiotics, most of which are amoxicillin, clarithromycin, etc. Since the metabolic enzymes of vonoprazan fumarate and clarithromycin are both CYP3A4, the two drugs will inhibit each other's metabolism, resulting in an increase in the blood concentration of vonoprazan fumarate.
相关研究表明,使用富马酸伏诺拉生和阿莫西林的二联疗法要比采用富马酸伏诺拉生、克拉霉素和阿莫西林的三联疗法治疗效果更佳。Related studies have shown that dual therapy with vonoprazan fumarate and amoxicillin is more effective than triple therapy with vonoprazan fumarate, clarithromycin, and amoxicillin.
富马酸伏诺拉生经口服进入肠胃后,2h即可达到血药峰值浓度,4小时内可将胃内pH值提高到4.0以上,药物半衰期约5.7-8.8小时,富马酸伏诺拉生体外蛋白结合率为85.2-88.0%,主要在肝脏代谢。健康成年男性受试者接受放射性标记药物(伏诺拉生15mg)口给药后168小时,98.5%的放射性药物排泄至尿液和粪便中:67.4%药物排泄尿液,31.1%药物排泄至粪便。After vonoprazan fumarate is taken orally and enters the stomach, it can reach the peak blood concentration in 2 hours, and the pH value in the stomach can be increased to above 4.0 within 4 hours. The half-life of the drug is about 5.7-8.8 hours. The in vitro protein binding rate of vonoprazan fumarate is 85.2-88.0%, and it is mainly metabolized in the liver. 168 hours after the oral administration of radiolabeled drugs (vonoprazan 15 mg) to healthy adult male subjects, 98.5% of the radioactive drugs were excreted into urine and feces: 67.4% of the drugs were excreted in urine, and 31.1% of the drugs were excreted into feces.
阿莫西林口服给药后吸收迅速,口服后阿莫西林的生物利用度约为70%,血药浓度达峰时间约为1-2h。食物对药物吸收没有显著影响,阿莫西林的蛋白结合率为17-20%,平均清除半衰期约为1h。单次给予250mg或500mg阿莫西林,6小时内大约45-68%的阿莫西林以原型药形式自尿液中排出。Amoxicillin is rapidly absorbed after oral administration. The bioavailability of amoxicillin after oral administration is about 70%, and the peak time of blood drug concentration is about 1-2 hours. Food has no significant effect on drug absorption. The protein binding rate of amoxicillin is 17-20%, and the average elimination half-life is about 1 hour. After a single administration of 250mg or 500mg amoxicillin, about 45-68% of amoxicillin is excreted from the urine in the form of the original drug within 6 hours.
现有的根除幽门螺杆菌三联疗法中,存在每日服药次数多、服药量大的问题,若是采用四联疗法,则服药量更是大大增加,降低了患者的服药意愿及配合程度。根除幽门螺杆菌的治疗周期往往需要两周及以上,且不同药物的服药数量及次数、饭前饭后服用等性质的不同,对中老年患者的治疗过程并不友好,且增加了肾脏负担。The existing triple therapy for eradicating Helicobacter pylori has the problem of multiple daily medications and large dosages. If quadruple therapy is used, the dosage will be greatly increased, which reduces the patient's willingness to take medication and their degree of cooperation. The treatment cycle for eradicating Helicobacter pylori often takes two weeks or more, and different drugs require different quantities and frequencies of medication, and whether to take them before or after meals. This is not friendly to the treatment process of middle-aged and elderly patients, and increases the burden on the kidneys.
现有的有关富马酸伏诺拉生和阿莫西林的复方制剂中,多是在富马酸伏诺拉生原有的处方基础上通过内加阿莫西林的方式完成复方制剂的制备,此种制备方式忽略了不同药物活性成分之间所需药物微环境及pH的不同,所制备出的复方制剂往往存在批内及批间药物溶出度不稳定,经放置稳定性测试后,出现药物的释放及溶出变慢或出现药物降解等情况,对药品质量产生严重的影响。Among the existing compound preparations of vonoprazan fumarate and amoxicillin, most are prepared by adding amoxicillin to the original prescription of vonoprazan fumarate. This preparation method ignores the differences in drug microenvironment and pH required for different active ingredients of the drugs. The prepared compound preparations often have unstable drug dissolution within and between batches. After the storage stability test, the release and dissolution of the drug slow down or the drug degradation occurs, which has a serious impact on the quality of the drug.
中国专利CN114053239A公开了一种富马酸伏诺拉生药物组合物及制备方法,通过在包衣过程中添加共聚维酮制备的富马酸伏诺拉生及其复方制剂,虽在高温高湿和强光照下具有良好的包衣膜稳定性和较低的有关物质,但也因为添加了共聚维酮而产生较多的不可控风险。由于共聚维酮极具吸湿性,其产品在长期存放中会出现溶出度变慢的情况,且因共聚维酮有很高的黏性,吸湿后会使片剂出现黏连的现象,导致制备的药物组合物的稳定性差,对药品的包装形式和药品的储存条件有着很高的要求。Chinese patent CN114053239A discloses a vonoprazan fumarate pharmaceutical composition and a preparation method thereof. The vonoprazan fumarate and its compound preparation prepared by adding copolyvidone in the coating process have good coating film stability and low related substances under high temperature, high humidity and strong light, but also produce more uncontrollable risks due to the addition of copolyvidone. Since copolyvidone is highly hygroscopic, its product will have a slow dissolution rate during long-term storage, and since copolyvidone has high viscosity, the tablets will stick together after absorbing moisture, resulting in poor stability of the prepared pharmaceutical composition, and high requirements are placed on the packaging form and storage conditions of the drug.
发明内容Summary of the invention
针对现有技术存在的不足,本发明提供了一种富马酸伏诺拉生制剂的制备方法,能够提高制剂的稳定性和溶出度,提高掩味效果。In view of the deficiencies in the prior art, the present invention provides a method for preparing a vonoprazan fumarate preparation, which can improve the stability and solubility of the preparation and improve the taste-masking effect.
为解决以上技术问题,本发明采取的技术方案如下:In order to solve the above technical problems, the technical solution adopted by the present invention is as follows:
一种富马酸伏诺拉生制剂的制备方法,由以下步骤组成:药物活性成分的预处理,粘合液配制,一步制粒,整粒,总混,压片,有机酸层包衣片的制备,药物层包衣片的制备,薄膜包衣片的制备;A preparation method of vonoprazan fumarate preparation, comprising the following steps: pretreatment of active pharmaceutical ingredients, preparation of a binding liquid, one-step granulation, granulation, total mixing, tableting, preparation of organic acid layer-coated tablets, preparation of drug layer-coated tablets, and preparation of film-coated tablets;
所述药物活性成分的预处理,将阿莫西林和富马酸伏诺拉生分别进行粉碎处理,得到粉碎后的阿莫西林和富马酸伏诺拉生;Pretreatment of the active ingredients of the medicine, crushing amoxicillin and vonoprazan fumarate respectively to obtain crushed amoxicillin and vonoprazan fumarate;
所述药物活性成分的预处理中,所述粉碎后的阿莫西林和富马酸伏诺拉生的粒径D90≤50μm;In the pretreatment of the active pharmaceutical ingredient, the particle size D90 of the crushed amoxicillin and vonoprazan fumarate is ≤50 μm;
所述粘合液配制,将过筛后的粘合剂与纯化水混合均匀,得到粘合液;The adhesive liquid is prepared by mixing the sieved adhesive with purified water to obtain an adhesive liquid;
所述粘合液配制中,粘合剂为聚维酮或羟丙甲纤维素中的一种或组合;In the preparation of the adhesive solution, the adhesive is one or a combination of povidone or hypromellose;
过筛后的粘合剂的粒径为80-100目;The particle size of the sieved adhesive is 80-100 mesh;
所述一步制粒,由以下步骤组成:物料混合,制粒;The one-step granulation comprises the following steps: material mixing and granulation;
所述物料混合,将粉碎后的阿莫西林、填充剂加入流化床物料室混合,得到阿莫西林混合料;The materials are mixed, and the crushed amoxicillin and filler are added into the fluidized bed material chamber for mixing to obtain an amoxicillin mixture;
所述物料混合中,所述填充剂为微晶纤维素、甘露醇、预胶化淀粉、纤维素-乳糖中的一种或几种;In the material mixing, the filler is one or more of microcrystalline cellulose, mannitol, pregelatinized starch, and cellulose-lactose;
流化床物料室的进风温度为60-70℃,进风风量为50-60m3/h,流化混合时间为3-5min;The inlet air temperature of the fluidized bed material chamber is 60-70°C, the inlet air volume is 50-60m 3 /h, and the fluidization mixing time is 3-5min;
所述制粒,将粘合液均匀喷至流化床物料室中阿莫西林混合料的表面,干燥,得到干颗粒;In the granulation, the binding liquid is evenly sprayed onto the surface of the amoxicillin mixture in the fluidized bed material chamber, and dried to obtain dry granules;
所述流化床物料室的进风温度60-70℃,进风风量45-55m3/h,雾化压力1.5-2bar,蠕动泵转速10-15rpm;The inlet air temperature of the fluidized bed material chamber is 60-70°C, the inlet air volume is 45-55m 3 /h, the atomization pressure is 1.5-2bar, and the peristaltic pump speed is 10-15rpm;
所述干颗粒的LOD≤1.5%;The LOD of the dry particles is ≤1.5%;
所述整粒,将干颗粒加入整粒机中进行整粒,得整粒颗粒;The granulation comprises adding the dry granules into a granulator for granulation to obtain granulated granules;
所述整粒中,整粒颗粒的粒径为1.2-1.5mm;In the granulation, the particle size of the granulated particles is 1.2-1.5 mm;
整粒机的转速为400-600rpm;The speed of the pelletizing machine is 400-600rpm;
所述总混,将整粒颗粒、崩解剂、颗粒润滑剂加入混合机混合均匀,得到总混颗粒;The total mixing includes adding the whole granules, disintegrant, and granule lubricant into a mixer and mixing them evenly to obtain total mixed granules;
所述总混中,所述崩解剂为羧甲淀粉钠、交联羧甲纤维素钠、交联聚维酮中的一种或几种;In the total mixture, the disintegrant is one or more of sodium carboxymethyl starch, croscarmellose sodium, and crospovidone;
所述颗粒润滑剂为硬脂酸镁、硬脂酸、硬脂富马酸钠中的一种或几种;The granular lubricant is one or more of magnesium stearate, stearic acid, and sodium stearyl fumarate;
混合机的主电机转速为高速40-50HZ,低速20-25HZ,混合时间为8-10min;The main motor speed of the mixer is 40-50HZ at high speed and 20-25HZ at low speed, and the mixing time is 8-10min;
所述压片,按照中心片重要求将总混颗粒加入压片机中进行压片,得到素片;The tableting comprises adding the total mixed granules into a tablet press according to the central tablet weight requirement to perform tableting to obtain a plain tablet;
所述压片机的主机转速为20-30rpm,主压力为10-20KN,预压力为3-6KN;The main machine speed of the tablet press is 20-30rpm, the main pressure is 10-20KN, and the pre-pressure is 3-6KN;
所述有机酸层包衣片的制备,由以下步骤组成:有机酸包衣液配制,有机酸层包衣;The preparation of the organic acid layer-coated tablets comprises the following steps: preparing an organic acid coating solution, and coating the organic acid layer;
所述有机酸包衣液配制,将过筛后的成膜材料和有机酸与纯化水混合均匀,得到有机酸包衣液;The organic acid coating solution is prepared by uniformly mixing the sieved film-forming material and the organic acid with purified water to obtain the organic acid coating solution;
所述有机酸包衣液配制中,所述成膜材料为羟丙甲纤维素、羧甲纤维素钠、聚维酮中的一种或几种;In the preparation of the organic acid coating solution, the film-forming material is one or more of hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and povidone;
所述有机酸为富马酸;The organic acid is fumaric acid;
过筛后的成膜材料和有机酸的粒径为80-100目;The particle size of the film-forming material and the organic acid after screening is 80-100 mesh;
所述有机酸层包衣,在包衣机中,将有机酸包衣液均匀喷至素片表面,包衣结束后干燥,得到有机酸层包衣片;The organic acid layer coating comprises spraying the organic acid coating liquid evenly onto the surface of the plain tablet in a coating machine, and drying after the coating is completed to obtain the organic acid layer coated tablet;
所述有机酸层包衣中,包衣机的热风温度为60-80℃,排风机转速为55-65%,包衣机转速为2-8rpm,雾化压力为0.4-0.6Mpa,蠕动泵转速为3.6-7rpm,片芯温度为40-50℃;In the organic acid layer coating, the hot air temperature of the coating machine is 60-80°C, the exhaust fan speed is 55-65%, the coating machine speed is 2-8rpm, the atomization pressure is 0.4-0.6Mpa, the peristaltic pump speed is 3.6-7rpm, and the tablet core temperature is 40-50°C;
所述药物层包衣片的制备,由以下步骤组成:药物层包衣液配制,药物层包衣;The preparation of the drug layer coated tablet comprises the following steps: preparing the drug layer coating solution and coating the drug layer;
所述药物层包衣液配制,将过筛后的成膜材料和增塑剂与纯化水混合均匀,加入粉碎后的富马酸伏诺拉生,混合均匀,得到药物层包衣液;The drug layer coating solution is prepared by mixing the sieved film-forming material and plasticizer with purified water, adding the crushed vonoprazan fumarate, and mixing them evenly to obtain the drug layer coating solution;
所述药物层包衣液配制中,所述成膜材料为羟丙甲纤维素或羟丙纤维素中的一种或组合;In the preparation of the drug layer coating solution, the film-forming material is one or a combination of hydroxypropyl methylcellulose or hydroxypropyl cellulose;
所述增塑剂为聚乙二醇6000、丙二醇、枸橼酸三乙酯中的一种或几种;The plasticizer is one or more of polyethylene glycol 6000, propylene glycol, and triethyl citrate;
过筛后的成膜材料和增塑剂的粒径均为80-100目;The particle sizes of the film-forming material and plasticizer after screening are both 80-100 mesh;
所述药物层包衣,在包衣机中,将药物层包衣液均匀喷至有机酸层包衣片表面,包衣结束后干燥,得到药物层包衣片;The drug layer coating comprises spraying the drug layer coating liquid evenly onto the surface of the organic acid layer coated tablet in a coating machine, and drying after the coating is completed to obtain the drug layer coated tablet;
所述药物层包衣中,包衣机的热风温度为40-60℃,排风机转速为55-65%,包衣机转速为2-8rpm,雾化压力为0.4-0.6Mpa,蠕动泵转速为4-10rpm,片芯温度为35-40℃;In the drug layer coating, the hot air temperature of the coating machine is 40-60°C, the exhaust fan speed is 55-65%, the coating machine speed is 2-8rpm, the atomization pressure is 0.4-0.6Mpa, the peristaltic pump speed is 4-10rpm, and the tablet core temperature is 35-40°C;
所述薄膜包衣片的制备,由以下步骤组成:薄膜包衣液配制,薄膜包衣;The preparation of the film-coated tablets comprises the following steps: preparing a film-coating solution and film coating;
所述薄膜包衣液配制,将过筛后的成膜材料溶于第一份纯化水中,得到成膜材料溶液;将过筛后的遮光剂和着色剂与第二份纯化水混合后均质,得到均质分散液;将均质后分散液加入成膜材料溶液中,搅拌均匀,得到薄膜包衣液;The film coating solution is prepared by dissolving the sieved film-forming material in the first portion of purified water to obtain a film-forming material solution; mixing the sieved sunscreen and colorant with the second portion of purified water and homogenizing to obtain a homogenous dispersion; adding the homogenized dispersion to the film-forming material solution and stirring evenly to obtain a film coating solution;
所述薄膜包衣液配制中,所述成膜材料为羟丙甲纤维素、羟丙纤维素、羧甲纤维素钠中的一种或几种;In the preparation of the film coating solution, the film-forming material is one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, and sodium carboxymethyl cellulose;
所述遮光剂为二氧化钛或滑石粉中的一种或组合;The sunscreen agent is one or a combination of titanium dioxide or talc;
所述着色剂为日落黄、氧化铁红、氧化铁黄中的一种或几种;The colorant is one or more of sunset yellow, red iron oxide, and yellow iron oxide;
过筛后的成膜材料及过筛后的遮光剂和着色剂的粒径均为80-100目;The particle sizes of the sieved film-forming material, sieved sunscreen agent and colorant are all 80-100 meshes;
第一份纯化水与第二份纯化水的质量比为1.5-2.5:1;The mass ratio of the first portion of purified water to the second portion of purified water is 1.5-2.5:1;
所述均质的均质时间为15-20min;The homogenization time of the homogenization is 15-20min;
所述薄膜包衣,在包衣机中,将薄膜包衣液均匀喷至药物层包衣片,包衣结束后干燥,得到富马酸伏诺拉生制剂;The film coating comprises spraying the film coating liquid evenly onto the drug layer coated tablets in a coating machine, and drying after the coating is completed to obtain the vonoprazan fumarate preparation;
所述薄膜包衣中,包衣机的热风温度为60-80℃,排风机转速为55-65%,包衣机转速为2-8rpm,雾化压力为0.4-0.6Mpa,蠕动泵转速为4-8rpm,片芯温度为38-42℃;In the film coating, the hot air temperature of the coating machine is 60-80°C, the exhaust fan speed is 55-65%, the coating machine speed is 2-8rpm, the atomization pressure is 0.4-0.6Mpa, the peristaltic pump speed is 4-8rpm, and the tablet core temperature is 38-42°C;
所述素片中使用的粉碎后的阿莫西林占富马酸伏诺拉生制剂中所有固体原料用量的质量分数为45-50%;The mass fraction of the crushed amoxicillin used in the plain tablets accounts for 45-50% of the total solid raw materials in the vonoprazan fumarate preparation;
所述素片中使用的填充剂占富马酸伏诺拉生制剂中所有固体原料用量的质量分数为23-25%;The filler used in the plain tablet accounts for 23-25% of the mass fraction of all solid raw materials in the vonoprazan fumarate preparation;
所述素片中使用的过筛后的粘合剂占富马酸伏诺拉生制剂中所有固体原料用量的质量分数为1.7-1.8%;The mass fraction of the sieved binder used in the plain tablets to all solid raw materials in the vonoprazan fumarate preparation is 1.7-1.8%;
所述素片中使用的崩解剂占富马酸伏诺拉生制剂中所有固体原料用量的质量分数为2.2-3%;The mass fraction of the disintegrant used in the plain tablets to all solid raw materials in the vonoprazan fumarate preparation is 2.2-3%;
所述素片中使用的颗粒润滑剂占富马酸伏诺拉生制剂中所有固体原料用量的质量分数为0.28-0.3%;The mass fraction of the granular lubricant used in the plain tablets to all solid raw materials in the vonoprazan fumarate preparation is 0.28-0.3%;
所述有机酸包衣液中使用的过筛后的成膜材料占富马酸伏诺拉生制剂中所有固体原料用量的质量分数为2.5-2.8%;The mass fraction of the sieved film-forming material used in the organic acid coating solution to all solid raw materials in the vonoprazan fumarate preparation is 2.5-2.8%;
所述有机酸包衣液中使用的过筛后的有机酸占富马酸伏诺拉生制剂中所有固体原料用量的质量分数为0.07-0.08%;The mass fraction of the sieved organic acid used in the organic acid coating solution to all solid raw materials in the vonoprazan fumarate preparation is 0.07-0.08%;
所述药物层包衣液中使用的粉碎后的富马酸伏诺拉生占富马酸伏诺拉生制剂中所有固体原料用量的质量分数为2.5-2.8%;The mass fraction of the crushed vonoprazan fumarate used in the drug layer coating liquid to all solid raw materials in the vonoprazan fumarate preparation is 2.5-2.8%;
所述药物层包衣液中使用的过筛后的成膜材料占富马酸伏诺拉生制剂中所有固体原料用量的质量分数为13-13.5%;The mass fraction of the sieved film-forming material used in the drug layer coating solution to all solid raw materials in the vonoprazan fumarate preparation is 13-13.5%;
所述药物层包衣液中使用的过筛后的增塑剂占富马酸伏诺拉生制剂中所有固体原料用量的质量分数为0.8-0.9%;The mass fraction of the sieved plasticizer used in the drug layer coating solution to all solid raw materials in the vonoprazan fumarate preparation is 0.8-0.9%;
所述薄膜包衣液中使用的过筛后的成膜材料占富马酸伏诺拉生制剂中所有固体原料用量的质量分数为3.2-3.5%;The mass fraction of the sieved film-forming material used in the film coating liquid to all solid raw materials in the vonoprazan fumarate preparation is 3.2-3.5%;
所述薄膜包衣液中使用的过筛后的遮光剂占富马酸伏诺拉生制剂中所有固体原料用量的质量分数为0.75-1.1%;The mass fraction of the sieved opacifier used in the film coating solution to all solid raw materials in the vonoprazan fumarate preparation is 0.75-1.1%;
所述薄膜包衣液中使用的过筛后的着色剂占富马酸伏诺拉生制剂中所有固体原料用量的质量分数为0.02-0.03%;The mass fraction of the sieved colorant used in the film coating liquid to all solid raw materials in the vonoprazan fumarate preparation is 0.02-0.03%;
所述素片中使用的粉碎后的阿莫西林与使用的纯化水的质量比为250:80-90;The mass ratio of the crushed amoxicillin used in the plain tablet to the purified water used is 250:80-90;
所述有机酸包衣液中使用的过筛后的有机酸与使用的纯化水的质量比为0.4:150-170;The mass ratio of the sieved organic acid used in the organic acid coating solution to the purified water used is 0.4:150-170;
所述药物层包衣液中使用的粉碎后的富马酸伏诺拉生与使用的纯化水的质量比为13-14:490-500;The mass ratio of the crushed vonoprazan fumarate used in the drug layer coating liquid to the purified water used is 13-14:490-500;
所述薄膜包衣液中使用的过筛后的成膜材料与使用的纯化水总量的质量比为17-18:150-170。The mass ratio of the sieved film-forming material used in the film coating solution to the total amount of purified water used is 17-18:150-170.
与现有技术相比,本发明的有益效果为:Compared with the prior art, the present invention has the following beneficial effects:
(1)本发明的富马酸伏诺拉生制剂的制备方法,不再拘泥于通过提供药物搭配或药物组合物的形式来治疗幽门螺杆菌,而是采用制剂手段将两种药物活性成分制于同一片型之中,达到单次服药即可与多品种药物多次服药相同的治疗效果,极大的减少了服药次数及服药数量,对中老年患者尤为友好;(1) The preparation method of the vonoprazan fumarate preparation of the present invention is no longer limited to treating Helicobacter pylori by providing a combination of drugs or a pharmaceutical composition, but adopts a preparation method to prepare two active ingredients of the drug in the same tablet form, so that a single dose can achieve the same therapeutic effect as multiple doses of multiple drugs, greatly reducing the number of medications and the amount of medication, which is particularly friendly to middle-aged and elderly patients;
(2)本发明的富马酸伏诺拉生制剂的制备方法,采用包衣的形式来提高口服的顺应性,避免药品与舌头直接接触而引发的不适感;(2) The preparation method of the vonoprazan fumarate preparation of the present invention adopts a coating form to improve the oral compliance and avoid the discomfort caused by direct contact between the drug and the tongue;
(3)本发明的富马酸伏诺拉生制剂的制备方法,能够提高富马酸伏诺拉生制剂的稳定性,制备的富马酸伏诺拉生制剂在加速条件为40±2℃,75±5%RH下加速3个月后溶出结构仍未发生明显下降,在25±2℃,60±5%RH条件下加速6个月后杂质仍未发生明显提高;(3) The preparation method of the vonoprazan fumarate preparation of the present invention can improve the stability of the vonoprazan fumarate preparation. The prepared vonoprazan fumarate preparation has no significant decrease in dissolution structure after being accelerated for 3 months at 40±2°C and 75±5%RH, and no significant increase in impurities after being accelerated for 6 months at 25±2°C and 60±5%RH.
(4)本发明的富马酸伏诺拉生制剂的制备方法,能够提高富马酸伏诺拉生制剂的溶出度,在富马酸伏诺拉生溶出测试中,60min后溶出度为99.3-100%,在阿莫西林溶出测试中,150min后溶出度为94.4-96.3%。(4) The preparation method of the vonoprazan fumarate preparation of the present invention can improve the solubility of the vonoprazan fumarate preparation. In the vonoprazan fumarate dissolution test, the solubility after 60 minutes is 99.3-100%, and in the amoxicillin dissolution test, the solubility after 150 minutes is 94.4-96.3%.
附图说明BRIEF DESCRIPTION OF THE DRAWINGS
图1为实施例1制备的富马酸伏诺拉生制剂的剂型示意图;FIG1 is a schematic diagram of the dosage form of the vonoprazan fumarate preparation prepared in Example 1;
图2为试验例中实施例1-4、对比例2、沃克富马酸伏诺拉生片参比制剂的富马酸伏诺拉生溶出曲线;FIG2 is a dissolution curve of vonoprazan fumarate of Examples 1-4, Comparative Example 2, and Walker's vonoprazan fumarate tablets reference preparation in the test examples;
图3为试验例中实施例1-4、对比例2、Sawacillin阿莫西林片参比制剂的阿莫西林溶出曲线。FIG. 3 is a dissolution curve of amoxicillin of Examples 1-4, Comparative Example 2, and Sawacillin Amoxicillin Tablets Reference Preparation in the Test Examples.
具体实施方式DETAILED DESCRIPTION
为了对本发明的技术特征、目的和效果有更加清楚的理解,现说明本发明的具体实施方式。In order to have a clearer understanding of the technical features, purposes and effects of the present invention, the specific implementation methods of the present invention are now described.
实施例1Example 1
一种富马酸伏诺拉生制剂,剂型示意图见图1所示。A vonoprazan fumarate preparation, the dosage form diagram of which is shown in FIG1 .
一种富马酸伏诺拉生制剂,单位制剂中的原料用量为:A vonoprazan fumarate preparation, wherein the amount of raw materials used in a unit preparation is:
一种富马酸伏诺拉生制剂的制备方法,具体为:A method for preparing a vonoprazan fumarate preparation, specifically comprising:
1.药物活性成分的预处理:将阿莫西林和富马酸伏诺拉生分别进行粉碎处理,控制原料药粒径D90≤50μm,得到粉碎后的阿莫西林和富马酸伏诺拉生。1. Pretreatment of active pharmaceutical ingredients: Amoxicillin and vonoprazan fumarate are pulverized separately to control the particle size D90 of the raw materials to ≤50 μm, thereby obtaining pulverized amoxicillin and vonoprazan fumarate.
2.粘合液配制:按照上表中的原料用量,将聚维酮过80目筛网后,称取处方量的聚维酮和纯化水,将聚维酮溶于纯化水中,搅拌分散均匀,得到粘合液。2. Preparation of adhesive solution: According to the raw material dosage in the above table, after passing the polyvidone through an 80-mesh sieve, weigh the prescribed amount of polyvidone and purified water, dissolve the polyvidone in the purified water, stir and disperse evenly, and obtain the adhesive solution.
3.一步制粒3. One-step granulation
3.1物料混合:按照上表中的原料用量,称取处方量的粉碎后的阿莫西林和纤维素-乳糖,将物料转移至流化床物料室内,设置进风温度60℃,进风风量50m3/h,流化混合3min。 3.1 Material mixing: According to the raw material dosage in the above table, weigh the prescribed amount of crushed amoxicillin and cellulose-lactose, transfer the materials to the fluidized bed material chamber, set the inlet air temperature to 60°C, the inlet air volume to 50m3 /h, and fluidize and mix for 3 minutes.
3.2制粒:设置进风温度70℃,进风风量55m3/h,雾化压力1.5bar,蠕动泵转速10rpm,将粘合液均匀喷至流化床物料室的物料表面并与物料均匀包裹,制粒完成后干燥,LOD≤1.5%,得干颗粒。3.2 Granulation: Set the air inlet temperature to 70°C, the air volume to 55m 3 /h, the atomization pressure to 1.5bar, and the peristaltic pump speed to 10rpm. Spray the binding liquid evenly onto the material surface of the fluidized bed material chamber and evenly wrap it with the material. After granulation, dry it and LOD ≤ 1.5% to obtain dry granules.
4.整粒:将干颗粒通过装有1.2mm筛网的整粒机中,设定多功能整粒机转速500rpm,得整粒颗粒。4. Granulation: The dry granules are passed through a granulator equipped with a 1.2 mm screen, and the speed of the multifunctional granulator is set to 500 rpm to obtain granules.
5.总混:按照上表中的原料用量,称取处方量的羧甲淀粉钠和硬脂富马酸钠,将整粒颗粒、羧甲淀粉钠、硬脂富马酸钠依次投入到料斗混合机物料桶内,调整混合机物料桶转速,设定主电机转速为高速40HZ,低速20HZ,混合时间为8min,得到总混颗粒。5. Total mixing: According to the raw material dosage in the above table, weigh the prescribed amount of sodium carboxymethyl starch and sodium stearyl fumarate, put the whole granules, sodium carboxymethyl starch and sodium stearyl fumarate into the material barrel of the hopper mixer in sequence, adjust the speed of the material barrel of the mixer, set the main motor speed to high speed 40HZ, low speed 20HZ, and the mixing time to 8min to obtain the total mixed granules.
6.压片:按照中心片重要求将总混颗粒加入压片机中进行压片,设置主机转速20rpm,主压力15KN,预压力4KN,制得合格素片。6. Tablet pressing: Add the total mixed granules into the tablet press for tablet pressing according to the central tablet weight requirements, set the main machine speed to 20rpm, the main pressure to 15KN, and the pre-pressure to 4KN to obtain qualified plain tablets.
7.有机酸层包衣片的制备7. Preparation of organic acid layer-coated tablets
7.1有机酸包衣液配制:按照上表中的原料用量,称取处方量的羟丙甲纤维素、富马酸、纯化水,将羟丙甲纤维素和富马酸溶于纯化水中搅拌至溶液澄清透明,得到有机酸包衣液,使用的原料在称取前先过80目筛网。7.1 Preparation of organic acid coating solution: According to the raw material dosage in the above table, weigh the prescribed amount of hydroxypropyl methylcellulose, fumaric acid and purified water, dissolve the hydroxypropyl methylcellulose and fumaric acid in purified water and stir until the solution is clear and transparent to obtain the organic acid coating solution. The raw materials used should be passed through an 80-mesh sieve before weighing.
7.2有机酸层包衣:将素片投入高效包衣机中,设置热风温度60℃,排风机转速55%,包衣机转速6rpm,雾化压力0.5Mpa,蠕动泵转速6rpm,将有机酸包衣液均匀喷至素片表面,包衣过程中控制片芯温度为45℃,包衣完成后进行干燥,得有机酸层包衣片。7.2 Organic acid layer coating: Put the plain tablets into a high-efficiency coating machine, set the hot air temperature to 60°C, the exhaust fan speed to 55%, the coating machine speed to 6rpm, the atomization pressure to 0.5Mpa, the peristaltic pump speed to 6rpm, and spray the organic acid coating liquid evenly onto the surface of the plain tablets. During the coating process, the tablet core temperature is controlled at 45°C. After coating, dry it to obtain organic acid layer coated tablets.
8.药物层包衣片的制备8. Preparation of drug-layer coated tablets
8.1药物层包衣液配制:按照上表中的原料用量,称取处方量的粉碎后的富马酸伏诺拉生、羟丙甲纤维素、枸橼酸三乙酯、纯化水,将羟丙甲纤维素和枸橼酸三乙酯溶于纯化水中搅拌至溶液透明,加入富马酸伏诺拉生继续搅拌至溶解,得到药物层包衣液,原料在称取前均先过80目筛网。8.1 Preparation of drug layer coating solution: According to the raw material dosage in the above table, weigh the prescribed amount of crushed vonoprazan fumarate, hydroxypropyl methylcellulose, triethyl citrate and purified water, dissolve hydroxypropyl methylcellulose and triethyl citrate in purified water and stir until the solution is transparent, add vonoprazan fumarate and continue stirring until dissolved to obtain a drug layer coating solution. The raw materials are sieved through an 80-mesh sieve before weighing.
8.2药物层包衣:将有机酸层包衣片投入高效包衣机中,设置热风温度60℃,排风机转速65%,包衣机转速6rpm,雾化压力0.5Mpa,蠕动泵转速5rpm,将药物层包衣液均匀喷至片剂表面,包衣过程中控制片芯温度为38℃,包衣完成后进行干燥,得药物层包衣片。8.2 Drug layer coating: Put the organic acid layer coated tablets into a high-efficiency coating machine, set the hot air temperature to 60°C, the exhaust fan speed to 65%, the coating machine speed to 6rpm, the atomization pressure to 0.5Mpa, the peristaltic pump speed to 5rpm, and spray the drug layer coating liquid evenly onto the tablet surface. During the coating process, the tablet core temperature is controlled at 38°C. After coating, dry it to obtain the drug layer coated tablets.
9.薄膜包衣片的制备9. Preparation of Film-Coated Tablets
9.1薄膜包衣液配制:按照上表中的原料用量,称取处方量的羟丙甲纤维素、二氧化钛、氧化铁红和2/3处方量的纯化水,将羟丙甲纤维素溶于2/3处方量的纯化水中搅拌溶解,得到羟丙甲纤维素溶液;二氧化钛和氧化铁红加入1/3处方量的纯化水中,使用均质机均质处理15min,得到均质分散液;随后将均质后分散液加入羟丙甲纤维素溶液中,继续搅拌60min,得到薄膜包衣液,原料在称取前先过80目筛网。9.1 Preparation of film coating solution: According to the raw material dosage in the above table, weigh the prescribed amount of hydroxypropyl methylcellulose, titanium dioxide, red iron oxide and 2/3 of the prescribed amount of purified water, dissolve the hydroxypropyl methylcellulose in 2/3 of the prescribed amount of purified water and stir to dissolve to obtain a hydroxypropyl methylcellulose solution; add titanium dioxide and red iron oxide to 1/3 of the prescribed amount of purified water, use a homogenizer to homogenize for 15 minutes to obtain a homogenous dispersion; then add the homogenized dispersion to the hydroxypropyl methylcellulose solution, continue stirring for 60 minutes to obtain a film coating solution. The raw materials are sieved through an 80-mesh sieve before being weighed.
9.2薄膜包衣:将药物层包衣片投入高效包衣机中,设置热风温度60℃,排风机转速55%,包衣机转速6rpm,雾化压力0.5Mpa,蠕动泵转速6rpm,将薄膜包衣液均匀喷至片剂表面,包衣过程中控制片芯温度在40℃,包衣完成后进行干燥,得富马酸伏诺拉生制剂。9.2 Film coating: Put the drug layer coated tablets into a high-efficiency coating machine, set the hot air temperature to 60°C, the exhaust fan speed to 55%, the coating machine speed to 6rpm, the atomization pressure to 0.5Mpa, the peristaltic pump speed to 6rpm, and spray the film coating liquid evenly onto the tablet surface. During the coating process, the tablet core temperature is controlled at 40°C. After coating, dry it to obtain the vonoprazan fumarate preparation.
实施例2Example 2
一种富马酸伏诺拉生制剂,单位制剂中的原料用量为:A vonoprazan fumarate preparation, wherein the amount of raw materials used in a unit preparation is:
一种富马酸伏诺拉生制剂的制备方法,具体为:A method for preparing a vonoprazan fumarate preparation, specifically comprising:
1.药物活性成分的预处理:将阿莫西林和富马酸伏诺拉生分别进行粉碎处理,控制原料药粒径D90≤50μm,得到粉碎后的阿莫西林和富马酸伏诺拉生。1. Pretreatment of active pharmaceutical ingredients: Amoxicillin and vonoprazan fumarate are pulverized separately to control the particle size D90 of the raw materials to ≤50 μm, thereby obtaining pulverized amoxicillin and vonoprazan fumarate.
2.粘合液配制:按照上表中的原料用量,将聚维酮过80目筛网后,称取处方量的聚维酮和纯化水,将聚维酮溶于纯化水中,搅拌分散均匀,得到粘合液。2. Preparation of adhesive solution: According to the raw material dosage in the above table, after passing the polyvidone through an 80-mesh sieve, weigh the prescribed amount of polyvidone and purified water, dissolve the polyvidone in the purified water, stir and disperse evenly, and obtain the adhesive solution.
3.一步制粒3. One-step granulation
3.1物料混合:按照上表中的原料用量,称取处方量的粉碎后的阿莫西林和预胶化淀粉,将物料转移至流化床物料室内,设置进风温度60℃,进风风量50m3/h,流化混合3min。 3.1 Material mixing: According to the raw material dosage in the above table, weigh the prescribed amount of crushed amoxicillin and pregelatinized starch, transfer the materials to the fluidized bed material chamber, set the inlet air temperature to 60°C, the inlet air volume to 50m3 /h, and fluidize and mix for 3 minutes.
3.2制粒:设置进风温度70℃,进风风量55m3/h,雾化压力1.5bar,蠕动泵转速10rpm,将粘合液均匀喷至物料表面并与物料均匀包裹。制粒完成后干燥,LOD≤1.5%,得干颗粒。3.2 Granulation: Set the air inlet temperature to 70℃, the air volume to 55m3 /h, the atomization pressure to 1.5bar, and the peristaltic pump speed to 10rpm. Spray the adhesive liquid evenly onto the surface of the material and wrap it evenly with the material. After granulation, dry it and LOD≤1.5% to obtain dry granules.
4.整粒:将干颗粒通过装有1.2mm筛网的整粒机中,设定多功能整粒机转速500rpm,得整粒颗粒。4. Granulation: The dry granules are passed through a granulator equipped with a 1.2 mm screen, and the speed of the multifunctional granulator is set to 500 rpm to obtain granules.
5.总混:按照上表中的原料用量,称取处方量的交联聚维酮和硬脂酸镁,将整粒颗粒、交联聚维酮、硬脂酸镁依次投入到料斗混合机物料桶内,调整混合机物料桶转速,设定主电机转速为高速40HZ,低速20HZ,混合时间为8min,得到总混颗粒。5. Total mixing: According to the raw material dosage in the above table, weigh the prescribed amount of cross-linked polyvinylpyrrolidone and magnesium stearate, put the whole granules, cross-linked polyvinylpyrrolidone and magnesium stearate into the material barrel of the hopper mixer in sequence, adjust the speed of the material barrel of the mixer, set the main motor speed to high speed 40HZ, low speed 20HZ, and the mixing time to 8min to obtain total mixed granules.
6.压片:按照中心片重要求将总混颗粒加入压片机中进行压片,设置主机转速20rpm,主压力15KN,预压力4KN,制得合格素片。6. Tablet pressing: Add the total mixed granules into the tablet press for tablet pressing according to the central tablet weight requirements, set the main machine speed to 20rpm, the main pressure to 15KN, and the pre-pressure to 4KN to obtain qualified plain tablets.
7.有机酸层包衣片的制备7. Preparation of organic acid layer-coated tablets
7.1有机酸包衣液配制:按照上表中的原料用量,按照处方量称取聚维酮、富马酸、纯化水,将聚维酮和富马酸溶于纯化水中搅拌至溶液澄清透明,得到有机酸包衣液,称取前先过80目筛网。7.1 Preparation of organic acid coating solution: According to the raw material dosage in the above table, weigh povidone, fumaric acid and purified water according to the prescription amount, dissolve povidone and fumaric acid in purified water and stir until the solution is clear and transparent to obtain organic acid coating solution, which should be sieved through an 80-mesh sieve before weighing.
7.2有机酸层包衣:将素片投入高效包衣机中,设置热风温度60℃,排风机转速55%,包衣机转速6rpm,雾化压力0.5Mpa,蠕动泵转速6rpm,将有机酸包衣液均匀喷至素片表面,包衣过程中控制片芯温度在45℃,包衣完成后进行干燥,得有机酸层包衣片。7.2 Organic acid layer coating: Put the plain tablets into a high-efficiency coating machine, set the hot air temperature to 60°C, the exhaust fan speed to 55%, the coating machine speed to 6rpm, the atomization pressure to 0.5Mpa, the peristaltic pump speed to 6rpm, and spray the organic acid coating liquid evenly onto the surface of the plain tablets. During the coating process, the tablet core temperature is controlled at 45°C. After coating, dry it to obtain organic acid layer coated tablets.
8.药物层包衣片的制备8. Preparation of drug-layer coated tablets
8.1药物层包衣液配制:按照上表中的原料用量,称取处方量的富马酸伏诺拉生、羟丙甲纤维素、枸橼酸三乙酯、纯化水,将羟丙甲纤维素和枸橼酸三乙酯溶于纯化水中搅拌至溶液透明,加入富马酸伏诺拉生继续搅拌至溶解,得到药物层包衣液,原料在称取前均先过80目筛网。8.1 Preparation of drug layer coating solution: According to the raw material dosage in the above table, weigh the prescribed amount of vonoprazan fumarate, hydroxypropyl methylcellulose, triethyl citrate and purified water, dissolve hydroxypropyl methylcellulose and triethyl citrate in purified water and stir until the solution is transparent, add vonoprazan fumarate and continue stirring until dissolved to obtain a drug layer coating solution. The raw materials are all sieved with an 80-mesh screen before being weighed.
8.2药物层包衣:将有机酸层包衣片投入高效包衣机中,设置热风温度60℃,排风机转速65%,包衣机转速6rpm,雾化压力0.5Mpa,蠕动泵转速5rpm,将药物层包衣液均匀喷至片剂表面,包衣过程中控制片芯温度在38℃,包衣完成后进行干燥,得药物层包衣片。8.2 Drug layer coating: Put the organic acid layer coated tablets into a high-efficiency coating machine, set the hot air temperature to 60°C, the exhaust fan speed to 65%, the coating machine speed to 6rpm, the atomization pressure to 0.5Mpa, the peristaltic pump speed to 5rpm, and spray the drug layer coating liquid evenly onto the tablet surface. During the coating process, the tablet core temperature is controlled at 38°C. After coating, dry it to obtain the drug layer coated tablets.
9.薄膜包衣片的制备9. Preparation of Film-Coated Tablets
9.1薄膜包衣液配制:按照上表中的原料用量,称取处方量的羟丙纤维素、二氧化钛、氧化铁黄和2/3处方量的纯化水,将羟丙纤维素溶于2/3处方量的纯化水中搅拌溶解,得到羟丙纤维素溶液;二氧化钛和氧化铁黄加入1/3处方量的纯化水中,使用均质机均质处理15min,得到均质分散液;随后将均质后分散液加入羟丙纤维素溶液中,继续搅拌60min,得到薄膜包衣液,原料在称取前过80目筛网。9.1 Preparation of film coating solution: According to the raw material dosage in the above table, weigh the prescribed amount of hydroxypropyl cellulose, titanium dioxide, yellow iron oxide and 2/3 of the prescribed amount of purified water, dissolve the hydroxypropyl cellulose in 2/3 of the prescribed amount of purified water and stir to dissolve to obtain a hydroxypropyl cellulose solution; add titanium dioxide and yellow iron oxide to 1/3 of the prescribed amount of purified water, use a homogenizer to homogenize for 15 minutes to obtain a homogeneous dispersion; then add the homogenized dispersion to the hydroxypropyl cellulose solution, continue stirring for 60 minutes to obtain a film coating solution. The raw materials are sieved through an 80-mesh sieve before weighing.
9.2薄膜包衣:将药物层包衣片投入高效包衣机中,设置热风温度60℃,排风机转速55%,包衣机转速6rpm,雾化压力0.5Mpa,蠕动泵转速6rpm,将薄膜包衣液均匀喷至片剂表面,包衣过程中控制片芯温度在40℃,包衣完成后进行干燥,得富马酸伏诺拉生制剂。9.2 Film coating: Put the drug layer coated tablets into a high-efficiency coating machine, set the hot air temperature to 60°C, the exhaust fan speed to 55%, the coating machine speed to 6rpm, the atomization pressure to 0.5Mpa, the peristaltic pump speed to 6rpm, and spray the film coating liquid evenly onto the tablet surface. During the coating process, the tablet core temperature is controlled at 40°C. After coating, dry it to obtain the vonoprazan fumarate preparation.
实验例3Experimental Example 3
一种富马酸伏诺拉生制剂,单位制剂中的原料用量为:A vonoprazan fumarate preparation, wherein the amount of raw materials used in a unit preparation is:
一种富马酸伏诺拉生制剂的制备方法,具体为:A method for preparing a vonoprazan fumarate preparation, specifically comprising:
1.药物活性成分的预处理:将阿莫西林和富马酸伏诺拉生分别进行粉碎处理,控制原料药粒径D90≤50μm,得到粉碎后的阿莫西林和富马酸伏诺拉生。1. Pretreatment of active pharmaceutical ingredients: Amoxicillin and vonoprazan fumarate are pulverized separately to control the particle size D90 of the raw materials to ≤50 μm, thereby obtaining pulverized amoxicillin and vonoprazan fumarate.
2.粘合液配制:按照上表中的原料用量,称取处方量的羟丙甲纤维素和纯化水,羟丙甲纤维素溶于纯化水中,搅拌分散均匀,得到粘合液。2. Preparation of adhesive solution: According to the raw material dosage in the above table, weigh the prescribed amount of hypromellose and purified water, dissolve the hypromellose in purified water, stir and disperse evenly to obtain an adhesive solution.
3.一步制粒3. One-step granulation
3.1物料混合:按照上表中的原料用量,称取处方量的粉碎后的阿莫西林和甘露醇,将物料转移至流化床物料室内,设置进风温度60℃,进风风量50m3/h,流化混合3min。 3.1 Material mixing: According to the raw material dosage in the above table, weigh the prescribed amount of crushed amoxicillin and mannitol, transfer the materials to the fluidized bed material chamber, set the inlet air temperature to 60°C, the inlet air volume to 50m3 /h, and fluidize and mix for 3 minutes.
3.2制粒:设置进风温度70℃,进风风量55m3/h,雾化压力1.5bar,蠕动泵转速10rpm,将粘合液均匀喷至物料表面并与物料均匀包裹,制粒完成后干燥,LOD≤1.5%,得干颗粒。3.2 Granulation: Set the air inlet temperature to 70℃, the air volume to 55m3 /h, the atomization pressure to 1.5bar, and the peristaltic pump speed to 10rpm. Spray the adhesive liquid evenly onto the surface of the material and wrap it evenly with the material. After granulation, dry it and LOD≤1.5% to obtain dry granules.
4.整粒:将干颗粒通过装有1.2mm筛网的整粒机中,设定多功能整粒机转速500rpm,得整粒颗粒。4. Granulation: The dry granules are passed through a granulator equipped with a 1.2 mm screen, and the speed of the multifunctional granulator is set to 500 rpm to obtain granules.
5.总混:按照上表中的原料用量,称取处方量的羧甲淀粉钠和硬脂富马酸钠,将整粒颗粒、羧甲淀粉钠、硬脂富马酸钠依次投入到料斗混合机物料桶内,调整混合机物料桶转速,设定主电机转速为高速40HZ,低速20HZ,混合时间为8min,得到总混颗粒。5. Total mixing: According to the raw material dosage in the above table, weigh the prescribed amount of sodium carboxymethyl starch and sodium stearyl fumarate, put the whole granules, sodium carboxymethyl starch and sodium stearyl fumarate into the material barrel of the hopper mixer in sequence, adjust the speed of the material barrel of the mixer, set the main motor speed to high speed 40HZ, low speed 20HZ, and the mixing time to 8min to obtain the total mixed granules.
6.压片:按照中心片重要求将总混颗粒加入压片机中进行压片,设置主机转速20rpm、主压力15KN,预压力4KN,制得合格素片。6. Tablet pressing: Add the total mixed granules into the tablet press according to the central tablet weight requirements for tablet pressing, set the main machine speed to 20rpm, the main pressure to 15KN, and the pre-pressure to 4KN to obtain qualified plain tablets.
7.有机酸层包衣片的制备7. Preparation of organic acid layer-coated tablets
7.1有机酸包衣液配制:按照上表中的原料用量,按照处方量称取羧甲纤维素钠、富马酸、纯化水,将羧甲纤维素钠和富马酸溶于纯化水中搅拌至溶液澄清透明,得到有机酸包衣液,称取前先过80目筛网。7.1 Preparation of organic acid coating solution: According to the raw material dosage in the above table, weigh sodium carboxymethyl cellulose, fumaric acid and purified water according to the prescription amount, dissolve sodium carboxymethyl cellulose and fumaric acid in purified water and stir until the solution is clear and transparent to obtain organic acid coating solution, which should be sieved through an 80-mesh sieve before weighing.
7.2有机酸层包衣:将素片投入高效包衣机中,设置热风温度60℃,排风机转速55%,包衣机转速6rpm,雾化压力0.5Mpa,蠕动泵转速6rpm,将有机酸包衣液均匀喷至素片表面,包衣过程中控制片芯温度在45℃,包衣完成后进行干燥,得有机酸层包衣片。7.2 Organic acid layer coating: Put the plain tablets into a high-efficiency coating machine, set the hot air temperature to 60°C, the exhaust fan speed to 55%, the coating machine speed to 6rpm, the atomization pressure to 0.5Mpa, the peristaltic pump speed to 6rpm, and spray the organic acid coating liquid evenly onto the surface of the plain tablets. During the coating process, the tablet core temperature is controlled at 45°C. After coating, dry it to obtain organic acid layer coated tablets.
8.药物层包衣片的制备8. Preparation of drug-layer coated tablets
8.1药物层包衣液配制:按照上表中的原料用量,称取处方量的富马酸伏诺拉生、羟丙甲纤维素、丙二醇、纯化水,将羟丙甲纤维素和丙二醇溶于纯化水中搅拌至溶液透明,加入富马酸伏诺拉生继续搅拌至溶解,得到药物层包衣液,原料在称取前均先过80目筛网。8.1 Preparation of drug layer coating solution: According to the raw material dosage in the above table, weigh the prescribed amount of vonoprazan fumarate, hypromellose, propylene glycol, and purified water, dissolve the hypromellose and propylene glycol in purified water and stir until the solution is transparent, add vonoprazan fumarate and continue stirring until dissolved to obtain the drug layer coating solution. The raw materials are all sieved with an 80-mesh screen before being weighed.
8.2药物层包衣:将有机酸层包衣片投入高效包衣机中,设置热风温度60℃,排风机转速65%,包衣机转速6rpm,雾化压力0.5Mpa,蠕动泵转速5rpm,将药物层包衣液均匀喷至片剂表面,包衣过程中控制片芯温度在38℃,包衣完成后进行干燥,得药物层包衣片。8.2 Drug layer coating: Put the organic acid layer coated tablets into a high-efficiency coating machine, set the hot air temperature to 60°C, the exhaust fan speed to 65%, the coating machine speed to 6rpm, the atomization pressure to 0.5Mpa, the peristaltic pump speed to 5rpm, and spray the drug layer coating liquid evenly onto the tablet surface. During the coating process, the tablet core temperature is controlled at 38°C. After coating, dry it to obtain the drug layer coated tablets.
9.薄膜包衣片的制备9. Preparation of Film-Coated Tablets
9.1薄膜包衣液配制:按照上表中的原料用量,称取处方量的羟丙甲纤维素、滑石粉、氧化铁红和2/3处方量的纯化水,将羟丙甲纤维素溶于2/3处方量的纯化水中搅拌溶解,得到羟丙甲纤维素溶液;滑石粉和氧化铁红加入1/3处方量的纯化水中,使用均质机均质处理15min,得到均质分散液;随后将均质后分散液加入羟丙甲纤维素溶液中,继续搅拌60min,得到薄膜包衣液,原料在称取前先过80目筛网。9.1 Preparation of film coating solution: According to the raw material dosage in the above table, weigh the prescribed amount of hydroxypropyl methylcellulose, talcum powder, red iron oxide and 2/3 of the prescribed amount of purified water, dissolve the hydroxypropyl methylcellulose in 2/3 of the prescribed amount of purified water and stir to dissolve to obtain a hydroxypropyl methylcellulose solution; add talcum powder and red iron oxide to 1/3 of the prescribed amount of purified water, use a homogenizer to homogenize for 15 minutes to obtain a homogenous dispersion; then add the homogenized dispersion to the hydroxypropyl methylcellulose solution, continue stirring for 60 minutes to obtain a film coating solution. The raw materials are sieved through an 80-mesh sieve before being weighed.
9.2薄膜包衣:将药物层包衣片投入高效包衣机中,设置热风温度60℃,排风机转速55%,包衣机转速6rpm,雾化压力0.5Mpa,蠕动泵转速6rpm,将薄膜包衣液均匀喷至片剂表面,包衣过程中控制片芯温度在40℃,包衣完成后进行干燥,得富马酸伏诺拉生制剂。9.2 Film coating: Put the drug layer coated tablets into a high-efficiency coating machine, set the hot air temperature to 60°C, the exhaust fan speed to 55%, the coating machine speed to 6rpm, the atomization pressure to 0.5Mpa, the peristaltic pump speed to 6rpm, and spray the film coating liquid evenly onto the tablet surface. During the coating process, the tablet core temperature is controlled at 40°C. After coating, dry it to obtain the vonoprazan fumarate preparation.
实施例4Example 4
一种富马酸伏诺拉生制剂,单位制剂中的原料用量为:A vonoprazan fumarate preparation, wherein the amount of raw materials used in a unit preparation is:
一种富马酸伏诺拉生制剂的制备方法,具体为:A method for preparing a vonoprazan fumarate preparation, specifically comprising:
1.药物活性成分的预处理:将阿莫西林和富马酸伏诺拉生分别进行粉碎处理,控制原料药粒径D90≤50μm,得到粉碎后的阿莫西林和富马酸伏诺拉生。1. Pretreatment of active pharmaceutical ingredients: Amoxicillin and vonoprazan fumarate are pulverized separately to control the particle size D90 of the raw materials to ≤50 μm, thereby obtaining pulverized amoxicillin and vonoprazan fumarate.
2.粘合液配制:按照上表中的原料用量,将聚维酮过80目筛网后,称取处方量的聚维酮和纯化水,将聚维酮溶于纯化水中,搅拌分散均匀,得到粘合液,称取前过80目筛网。2. Preparation of adhesive liquid: according to the raw material dosage in the above table, after passing the polyvidone through an 80-mesh sieve, weigh the prescribed amount of polyvidone and purified water, dissolve the polyvidone in the purified water, stir and disperse evenly to obtain an adhesive liquid, and pass the weighed liquid through an 80-mesh sieve.
3.一步制粒3. One-step granulation
3.1物料混合:按照上表中的原料用量,称取处方量的阿莫西林和微晶纤维素,将物料转移至流化床物料室内,设置进风温度60℃,进风风量50m3/h,流化混合3min。 3.1 Material mixing: According to the raw material dosage in the above table, weigh the prescribed amount of amoxicillin and microcrystalline cellulose, transfer the materials to the fluidized bed material chamber, set the inlet air temperature to 60°C, the inlet air volume to 50m3 /h, and fluidize and mix for 3 minutes.
3.2制粒:设置进风温度70℃,进风风量55m3/h,雾化压力1.5bar,蠕动泵转速10rpm,将粘合液均匀喷至物料室的物料表面并与物料均匀包裹,制粒完成后干燥,LOD≤1.5%,得干颗粒。3.2 Granulation: Set the air inlet temperature to 70℃, the air volume to 55m3 /h, the atomization pressure to 1.5bar, and the peristaltic pump speed to 10rpm. Spray the adhesive liquid evenly onto the surface of the material in the material chamber and wrap it evenly with the material. After granulation, dry it and LOD≤1.5% to obtain dry granules.
4.整粒:将干颗粒通过装有1.2mm筛网的整粒机中,设定多功能整粒机转速500rpm,得整粒颗粒。4. Granulation: The dry granules are passed through a granulator equipped with a 1.2 mm screen, and the speed of the multifunctional granulator is set to 500 rpm to obtain granules.
5.总混:按照上表中的原料用量,称取处方量的交联羧甲纤维素钠和硬脂酸,将整粒颗粒、交联羧甲纤维素钠、硬脂酸依次投入到料斗混合机物料桶内,调整混合机物料桶转速,设定主电机转速为高速40HZ,低速20HZ,混合时间为8min,得到总混颗粒。5. Total mixing: According to the raw material dosage in the above table, weigh the prescribed amount of cross-linked carboxymethyl cellulose sodium and stearic acid, put the whole granules, cross-linked carboxymethyl cellulose sodium and stearic acid into the material barrel of the hopper mixer in sequence, adjust the speed of the mixer material barrel, set the main motor speed to high speed 40HZ, low speed 20HZ, and the mixing time to 8min to obtain total mixed particles.
6.压片:按照中心片重要求将总混颗粒加入压片机中进行压片,设置主机转速20rpm、主压力15KN,预压力4KN,制得合格素片。6. Tablet pressing: Add the total mixed granules into the tablet press according to the central tablet weight requirements for tablet pressing, set the main machine speed to 20rpm, the main pressure to 15KN, and the pre-pressure to 4KN to obtain qualified plain tablets.
7.有机酸层包衣片的制备7. Preparation of organic acid layer-coated tablets
7.1有机酸包衣液配制:按照上表中的原料用量,按照处方量称取羟丙甲纤维素、富马酸、纯化水,将羟丙甲纤维素和富马酸溶于纯化水中搅拌至溶液澄清透明,得到有机酸包衣液,使用的原料在称取前过80目筛网过筛备用。7.1 Preparation of organic acid coating solution: According to the raw material dosage in the above table, weigh out hydroxypropyl methylcellulose, fumaric acid and purified water according to the prescription amount, dissolve hydroxypropyl methylcellulose and fumaric acid in purified water and stir until the solution is clear and transparent to obtain the organic acid coating solution. The raw materials used should be sieved through an 80-mesh sieve before weighing and set aside.
7.2有机酸层包衣:将素片投入高效包衣机中,设置热风温度60℃,排风机转速55%,包衣机转速6rpm,雾化压力0.5Mpa,蠕动泵转速6rpm,将有机酸包衣液均匀喷至素片表面,包衣过程中控制片芯温度在45℃,包衣完成后进行干燥,得有机酸层包衣片。7.2 Organic acid layer coating: Put the plain tablets into a high-efficiency coating machine, set the hot air temperature to 60°C, the exhaust fan speed to 55%, the coating machine speed to 6rpm, the atomization pressure to 0.5Mpa, the peristaltic pump speed to 6rpm, and spray the organic acid coating liquid evenly onto the surface of the plain tablets. During the coating process, the tablet core temperature is controlled at 45°C. After coating, dry it to obtain organic acid layer coated tablets.
8.药物层包衣片的制备8. Preparation of drug-layer coated tablets
8.1药物层包衣液配制:按照上表中的原料用量,称取处方量的富马酸伏诺拉生、羟丙纤维素、枸橼酸三乙酯、纯化水,将羟丙纤维素和枸橼酸三乙酯溶于纯化水中搅拌至溶液透明,加入富马酸伏诺拉生继续搅拌至溶解,得到药物层包衣液,原料在称取前均先过80目筛网。8.1 Preparation of drug layer coating solution: According to the raw material dosage in the above table, weigh the prescribed amount of vonoprazan fumarate, hydroxypropyl cellulose, triethyl citrate and purified water, dissolve hydroxypropyl cellulose and triethyl citrate in purified water and stir until the solution is transparent, add vonoprazan fumarate and continue stirring until dissolved to obtain a drug layer coating solution. The raw materials are all sieved with an 80-mesh screen before being weighed.
8.2药物层包衣:将有机酸层包衣片投入高效包衣机中,设置热风温度60℃,排风机转速65%,包衣机转速6rpm,雾化压力0.5Mpa,蠕动泵转速5rpm,将药物层包衣液均匀喷至片剂表面,包衣过程中控制片芯温度在38℃,包衣完成后进行干燥,得药物层包衣片。8.2 Drug layer coating: Put the organic acid layer coated tablets into a high-efficiency coating machine, set the hot air temperature to 60°C, the exhaust fan speed to 65%, the coating machine speed to 6rpm, the atomization pressure to 0.5Mpa, the peristaltic pump speed to 5rpm, and spray the drug layer coating liquid evenly onto the tablet surface. During the coating process, the tablet core temperature is controlled at 38°C. After coating, dry it to obtain the drug layer coated tablets.
9.薄膜包衣片的制备9. Preparation of Film-Coated Tablets
9.1薄膜包衣液配制:按照上表中的原料用量,称取处方量的羧甲纤维素钠、二氧化钛、日落黄和2/3处方量的纯化水,将羧甲纤维素钠溶于2/3处方量的纯化水中搅拌溶解,得到羟甲纤维素钠溶液;二氧化钛和日落黄加入1/3处方量的纯化水中,使用均质机均质处理15min,得到均质分散液;随后将均质后分散液加入羧甲纤维素钠溶液中,继续搅拌60min,得到薄膜包衣液,原料在称取前先过80目筛网。9.1 Preparation of film coating solution: According to the raw material dosage in the above table, weigh the prescribed amount of sodium carboxymethyl cellulose, titanium dioxide, sunset yellow and 2/3 of the prescribed amount of purified water, dissolve sodium carboxymethyl cellulose in 2/3 of the prescribed amount of purified water and stir to dissolve to obtain sodium carboxymethyl cellulose solution; add titanium dioxide and sunset yellow to 1/3 of the prescribed amount of purified water, use a homogenizer to homogenize for 15 minutes to obtain a homogenous dispersion; then add the homogenized dispersion to the sodium carboxymethyl cellulose solution, continue stirring for 60 minutes to obtain a film coating solution. The raw materials are sieved through an 80-mesh sieve before being weighed.
9.2薄膜包衣:将药物层包衣片投入高效包衣机中,设置热风温度60℃,排风机转速55%,包衣机转速6rpm,雾化压力0.5Mpa,蠕动泵转速6rpm,将薄膜包衣液均匀喷至片剂表面,包衣过程中控制片芯温度在40℃,包衣完成后进行干燥,得富马酸伏诺拉生制剂。9.2 Film coating: Put the drug layer coated tablets into a high-efficiency coating machine, set the hot air temperature to 60°C, the exhaust fan speed to 55%, the coating machine speed to 6rpm, the atomization pressure to 0.5Mpa, the peristaltic pump speed to 6rpm, and spray the film coating liquid evenly onto the tablet surface. During the coating process, the tablet core temperature is controlled at 40°C. After coating, dry it to obtain the vonoprazan fumarate preparation.
对比例1Comparative Example 1
参考中国专利CN114053239A中公开的制备方法制备富马酸伏诺拉生片,与实施例1制备的富马酸伏诺拉生制剂进行稳定性试验比较,在加速条件下进行,加速条件为40±2℃,75±5%RH,检验加速1个月、加速2个月、加速3个月的溶出结果。The preparation method disclosed in Chinese patent CN114053239A was used to prepare vonoprazan fumarate tablets, and the stability test was compared with the vonoprazan fumarate preparation prepared in Example 1. The test was carried out under accelerated conditions of 40±2°C and 75±5%RH, and the dissolution results of accelerated 1 month, accelerated 2 months, and accelerated 3 months were tested.
本对比例的富马酸伏诺拉生片,单位制剂中的原料用量为:The amount of raw materials used in the unit preparation of the vonoprazan fumarate tablets in this comparative example is:
本对比例的富马酸伏诺拉生片的制备方法为:The preparation method of the vonolazepam fumarate tablets of this comparative example is:
1.片芯制备:将富马酸伏诺拉生、甘露醇、微晶纤维素pH101过筛,置湿法混合制粒机(搅拌速度400rpm,剪切速度800rpm)中混合300s,加入占水溶液总重20%的羟丙纤维素和富马酸水溶液制备软材,摇摆颗粒机制粒(0.8mm筛网,转速500rpm过筛),将湿颗粒置于流化床制粒机中,使物料达到流化状态,维持物料温度30℃,喷涂剩余的羟丙纤维素和富马酸的水溶液,得到干颗粒(水分小于2%)。使获得的干颗粒通过20目筛,得到筛分的颗粒。将筛分的颗粒、交联羧甲基纤维素钠和硬脂酸镁放在混合机中设置高速40HZ,低速20HZ,混合15min,得到混合物料。1. Tablet core preparation: vornorazen fumarate, mannitol, and microcrystalline cellulose pH 101 are sieved and placed in a wet mixing granulator (stirring speed 400rpm, shear speed 800rpm) for 300s, and hydroxypropyl cellulose and fumaric acid aqueous solution accounting for 20% of the total weight of the aqueous solution are added to prepare a soft material, and the granulator is granulated (0.8mm screen, sieving at a speed of 500rpm), and the wet granules are placed in a fluidized bed granulator to make the material reach a fluidized state, maintain the material temperature at 30°C, and spray the remaining hydroxypropyl cellulose and fumaric acid aqueous solution to obtain dry granules (water content less than 2%). The obtained dry granules are passed through a 20-mesh sieve to obtain sieved granules. The sieved granules, cross-linked sodium carboxymethyl cellulose, and magnesium stearate are placed in a mixer and set at a high speed of 40HZ and a low speed of 20HZ, and mixed for 15min to obtain a mixed material.
利用旋转压片机,将该混合物料压片,得到片芯。The mixed material is tableted using a rotary tablet press to obtain tablet cores.
2.包衣:将上述片芯放在包衣机中,用加入预先配置的质量浓度为10%包衣水溶液喷涂(主机速度6r/min,喷雾压力0.6MPa,设定进风温度60℃,片床温度控制在40℃,喷雾速度8rpm),制得富马酸伏诺拉生片。2. Coating: Place the above tablet cores in a coating machine and spray with a pre-configured 10% mass concentration coating aqueous solution (main machine speed 6 r/min, spray pressure 0.6 MPa, set inlet air temperature 60°C, tablet bed temperature controlled at 40°C, spray speed 8 rpm) to obtain vonopraz fumarate raw tablets.
实施例1制备的富马酸伏诺拉生制剂与对比例1制备的富马酸伏诺拉生片的溶出结果如下:The dissolution results of the vonoprazan fumarate preparation prepared in Example 1 and the vonoprazan fumarate tablets prepared in Comparative Example 1 are as follows:
由上表可知,随着加速试验的延长,使用中国专利CN114053239A的技术方案制备的富马酸伏诺拉生片在溶出数据上呈现出快速下降的趋势,且专利方法制备的富马酸伏诺拉生片在放置过程中容易出现黏连的情况,片剂表面光滑度下降,而实施例1制备的富马酸伏诺拉生制剂则不存在该问题。As can be seen from the above table, with the extension of the accelerated test, the vonoprazan fumarate tablets prepared using the technical solution of Chinese patent CN114053239A showed a rapid downward trend in the dissolution data, and the vonoprazan fumarate tablets prepared by the patented method were prone to adhesion during the placement process, and the surface smoothness of the tablets decreased, while the vonoprazan fumarate preparation prepared in Example 1 did not have this problem.
对比例2Comparative Example 2
采用与实施例1相同的技术方案,其不同之处在于:将富马酸伏诺拉生加入片芯组分,将阿莫西林加入药物层中,本对比例的富马酸伏诺拉生制剂,单位制剂中的原料用量为:The same technical scheme as Example 1 is adopted, except that vonoprazan fumarate is added to the tablet core component, and amoxicillin is added to the drug layer. The amount of raw materials used in the vonoprazan fumarate preparation per unit preparation of this comparative example is:
本对比例的富马酸伏诺拉生制剂的制备方法为:The preparation method of the vonoprazan fumarate preparation of this comparative example is:
1.药物活性成分的预处理:将阿莫西林和富马酸伏诺拉生分别进行粉碎处理,控制原料药粒径D90≤50μm,得到粉碎后的阿莫西林和富马酸伏诺拉生。1. Pretreatment of active pharmaceutical ingredients: Amoxicillin and vonoprazan fumarate are pulverized separately to control the particle size D90 of the raw materials to ≤50 μm, thereby obtaining pulverized amoxicillin and vonoprazan fumarate.
2.粘合液配制:按照上表中的原料用量,将聚维酮过80目筛网后,称取处方量的聚维酮和纯化水,将聚维酮溶于纯化水中,搅拌分散均匀,得到粘合液。2. Preparation of adhesive solution: According to the raw material dosage in the above table, after passing the polyvidone through an 80-mesh sieve, weigh the prescribed amount of polyvidone and purified water, dissolve the polyvidone in the purified water, stir and disperse evenly, and obtain the adhesive solution.
3.一步制粒3. One-step granulation
3.1物料混合:按照上表中的原料用量,称取处方量的富马酸伏诺拉生和纤维素-乳糖,将物料转移至流化床物料室内,设置进风温度60℃,进风风量50m3/h,流化混合3min。 3.1 Material mixing: According to the raw material dosage in the above table, weigh the prescribed amount of vonoprazan fumarate and cellulose-lactose, transfer the materials to the fluidized bed material chamber, set the inlet air temperature to 60°C, the inlet air volume to 50m3 /h, and fluidize and mix for 3 minutes.
3.2制粒:设置进风温度70℃,进风风量55m3/h,雾化压力1.5bar,蠕动泵转速10rpm,将粘合液均匀喷至物料室的物料表面并与物料均匀包裹,制粒完成后干燥,LOD≤1.5%,得干颗粒。3.2 Granulation: Set the air inlet temperature to 70℃, the air volume to 55m3 /h, the atomization pressure to 1.5bar, and the peristaltic pump speed to 10rpm. Spray the adhesive liquid evenly onto the surface of the material in the material chamber and wrap it evenly with the material. After granulation, dry it and LOD≤1.5% to obtain dry granules.
4.整粒:将干颗粒通过装有1.2mm筛网的整粒机中,设定多功能整粒机转速500rpm,得整粒颗粒。4. Granulation: The dry granules are passed through a granulator equipped with a 1.2 mm screen, and the speed of the multifunctional granulator is set to 500 rpm to obtain granules.
5.总混:按照上表中的原料用量,称取处方量的羧甲淀粉钠和硬脂富马酸钠,将整粒颗粒、羧甲淀粉钠、硬脂富马酸钠依次投入到料斗混合机物料桶内,调整混合机物料桶转速,设定主电机转速为高速40HZ,低速20HZ,混合时间为8min,得到总混颗粒。5. Total mixing: According to the raw material dosage in the above table, weigh the prescribed amount of sodium carboxymethyl starch and sodium stearyl fumarate, put the whole granules, sodium carboxymethyl starch and sodium stearyl fumarate into the material barrel of the hopper mixer in sequence, adjust the speed of the material barrel of the mixer, set the main motor speed to high speed 40HZ, low speed 20HZ, and the mixing time to 8min to obtain the total mixed granules.
6.压片:按照中心片重要求将总混颗粒加入压片机中进行压片,设置主机转速20rpm,主压力15KN,预压力4KN,制得合格素片。6. Tablet pressing: Add the total mixed granules into the tablet press for tablet pressing according to the central tablet weight requirements, set the main machine speed to 20rpm, the main pressure to 15KN, and the pre-pressure to 4KN to obtain qualified plain tablets.
7.有机酸层包衣片的制备7. Preparation of organic acid layer-coated tablets
7.1有机酸包衣液配制:按照上表中的原料用量,按照处方量称取羟丙甲纤维素、富马酸、纯化水,将羟丙甲纤维素和富马酸溶于纯化水中搅拌至溶液澄清透明,得到有机酸包衣液,使用的原料在称取前先过80目筛网。7.1 Preparation of organic acid coating solution: According to the raw material dosage in the above table, weigh hydroxypropyl methylcellulose, fumaric acid and purified water according to the prescription amount, dissolve hydroxypropyl methylcellulose and fumaric acid in purified water and stir until the solution is clear and transparent to obtain organic acid coating solution. The raw materials used should be passed through an 80-mesh sieve before weighing.
7.2有机酸层包衣:将素片投入高效包衣机中,设置热风温度60℃,排风机转速55%,包衣机转速6rpm,雾化压力0.5Mpa,蠕动泵转速6rpm,将有机酸包衣液均匀喷至素片表面,包衣过程中控制片芯温度在45℃,包衣完成后进行干燥,得有机酸层包衣片。7.2 Organic acid layer coating: Put the plain tablets into a high-efficiency coating machine, set the hot air temperature to 60°C, the exhaust fan speed to 55%, the coating machine speed to 6rpm, the atomization pressure to 0.5Mpa, the peristaltic pump speed to 6rpm, and spray the organic acid coating liquid evenly onto the surface of the plain tablets. During the coating process, the tablet core temperature is controlled at 45°C. After coating, dry it to obtain organic acid layer coated tablets.
8.药物层包衣片的制备8. Preparation of drug-layer coated tablets
8.1药物层包衣液配制:称取处方量的阿莫西林、羟丙甲纤维素、枸橼酸三乙酯和纯化水,将羟丙甲纤维素和枸橼酸三乙酯溶于纯化水中搅拌至溶液透明,加入阿莫西林继续搅拌至溶解,得到药物层包衣液,原料在称取前均先过80目筛网。8.1 Preparation of drug layer coating solution: Weigh the prescribed amount of amoxicillin, hypromellose, triethyl citrate and purified water, dissolve the hypromellose and triethyl citrate in purified water and stir until the solution is transparent, add amoxicillin and continue stirring until dissolved to obtain the drug layer coating solution. All raw materials are sieved through an 80-mesh sieve before weighing.
8.2药物层包衣:将有机酸层包衣片投入高效包衣机中,设置热风温度60℃,排风机转速65%,包衣机转速6rpm,雾化压力0.5Mpa,蠕动泵转速5rpm,将药物层包衣液均匀喷至片剂表面,包衣过程中控制片芯温度在38℃,包衣完成后进行干燥,得药物层包衣片。8.2 Drug layer coating: Put the organic acid layer coated tablets into a high-efficiency coating machine, set the hot air temperature to 60°C, the exhaust fan speed to 65%, the coating machine speed to 6rpm, the atomization pressure to 0.5Mpa, the peristaltic pump speed to 5rpm, and spray the drug layer coating liquid evenly onto the tablet surface. During the coating process, the tablet core temperature is controlled at 38°C. After coating, dry it to obtain the drug layer coated tablets.
9.薄膜包衣片的制备9. Preparation of Film-Coated Tablets
9.1薄膜包衣液配制:按照上表中的原料用量,称取处方量的羟丙纤维素、二氧化钛、氧化铁红和2/3处方量的纯化水,将羟丙纤维素溶于2/3处方量的纯化水中搅拌溶解,得到羟丙甲纤维素溶液;二氧化钛和氧化铁红加入1/3处方量的纯化水中,并使用均质机均质处理15min,得到均质分散液;随后将均质后分散液加入羟丙纤维素溶液中,继续搅拌60min,得到薄膜包衣液,原料在称取前先过80目筛网。9.1 Preparation of film coating solution: According to the raw material dosage in the above table, weigh the prescribed amount of hydroxypropyl cellulose, titanium dioxide, red iron oxide and 2/3 of the prescribed amount of purified water, dissolve the hydroxypropyl cellulose in 2/3 of the prescribed amount of purified water and stir to dissolve to obtain a hydroxypropyl methylcellulose solution; add titanium dioxide and red iron oxide to 1/3 of the prescribed amount of purified water and use a homogenizer to homogenize for 15 minutes to obtain a homogenous dispersion; then add the homogenized dispersion to the hydroxypropyl cellulose solution and continue stirring for 60 minutes to obtain a film coating solution. The raw materials are sieved through an 80-mesh sieve before being weighed.
9.2薄膜包衣:将药物层包衣片投入高效包衣机中,设置热风温度60℃,排风机转速55%,包衣机转速6rpm,雾化压力0.5Mpa,蠕动泵转速6rpm,将薄膜包衣液均匀喷至片剂表面,包衣过程中控制片芯温度在40℃,包衣完成后进行干燥,得富马酸伏诺拉生制剂。9.2 Film coating: Put the drug layer coated tablets into a high-efficiency coating machine, set the hot air temperature to 60°C, the exhaust fan speed to 55%, the coating machine speed to 6rpm, the atomization pressure to 0.5Mpa, the peristaltic pump speed to 6rpm, and spray the film coating liquid evenly onto the tablet surface. During the coating process, the tablet core temperature is controlled at 40°C. After coating, dry it to obtain the vonoprazan fumarate preparation.
试验例Test example
对实施例和对比例制备的制剂进行产品溶出及稳定性检测,检测方法及检测结果如下:The preparations prepared in the examples and comparative examples were subjected to product dissolution and stability tests, and the test methods and test results are as follows:
1. 富马酸伏诺拉生溶出测试:1. Vonoprazan fumarate dissolution test:
溶出方法:Dissolution method:
所需仪器:电子天平、溶出度仪、高效液相色谱仪Required instruments: electronic balance, dissolution apparatus, high performance liquid chromatograph
方法:溶出度第二法(桨法)Method: Dissolution method II (paddle method)
温度:37.0℃Temperature: 37.0℃
转速:50rpmSpeed: 50rpm
检测波长:230nmDetection wavelength: 230nm
取样时间:5min、10min、15min、20min、30min、45min、60minSampling time: 5min, 10min, 15min, 20min, 30min, 45min, 60min
释放介质:pH4.5醋酸盐缓冲液;Release medium: pH 4.5 acetate buffer;
释放介质的制备方法:取三水乙酸钠2.99g(无水乙酸钠1.80g),加2mol/L乙酸溶液(114mL无水乙酸加水至1000mL)14.0mL,加水溶解并稀释至1000mL,调pH至4.5,摇匀。Preparation method of release medium: Take 2.99 g of sodium acetate trihydrate (1.80 g of anhydrous sodium acetate), add 14.0 mL of 2 mol/L acetic acid solution (114 mL of anhydrous acetic acid plus water to 1000 mL), add water to dissolve and dilute to 1000 mL, adjust the pH to 4.5, and shake well.
实施例1-4、对比例2、沃克富马酸伏诺拉生片参比制剂(沃克富马酸伏诺拉生片参比制剂由日本武田制药生产,商品名为沃克®,药品规格为20mg)在溶出介质中的溶出度及溶出曲线如下:The dissolution rate and dissolution curve of Examples 1-4, Comparative Example 2, and Walker's Vonoprazan Fumarate Tablets Reference Preparation (Walker's Vonoprazan Fumarate Tablets Reference Preparation is produced by Takeda Pharmaceuticals of Japan, with a trade name of Walker® and a drug specification of 20 mg) in the dissolution medium are as follows:
溶出度结果:Dissolution Results:
实施例1-4、对比例2、沃克富马酸伏诺拉生片参比制剂的富马酸伏诺拉生溶出曲线见图2所示。The dissolution curves of vonoprazan fumarate of Examples 1-4, Comparative Example 2, and Walker's vonoprazan fumarate tablets reference preparation are shown in FIG2 .
2.阿莫西林溶出测试:2. Amoxicillin dissolution test:
溶出方法:Dissolution method:
所需仪器:电子天平、溶出度仪、高效液相色谱仪Required instruments: electronic balance, dissolution apparatus, high performance liquid chromatograph
方法:溶出度第二法(桨法)Method: Dissolution method II (paddle method)
温度:37.0℃Temperature: 37.0℃
转速:100rpmSpeed: 100rpm
检测波长:254nmDetection wavelength: 254nm
取样时间:5min、10min、15min、30min、45min、60min、90min、120min、150minSampling time: 5min, 10min, 15min, 30min, 45min, 60min, 90min, 120min, 150min
释放介质:pH6.8磷酸二氢钾-氢氧化钠缓冲溶液Release medium: pH 6.8 potassium dihydrogen phosphate-sodium hydroxide buffer solution
释放介质的制备方法:取0.2mol/L磷酸二氢钾溶液250ml,加0.2mol/L氢氧化钠溶液118ml,用水稀释至1000ml,摇匀。Preparation method of release medium: Take 250 ml of 0.2 mol/L potassium dihydrogen phosphate solution, add 118 ml of 0.2 mol/L sodium hydroxide solution, dilute with water to 1000 ml, and shake well.
实施例1-4、对比例2、Sawacillin阿莫西林片参比制剂(阿莫西林片参比制剂由日本安斯泰来制药株式会社生产,商品名为Sawacillin®,药品规格为0.25g)在pH6.8溶出介质中溶出度及溶出曲线如下:The dissolution rate and dissolution curve of Examples 1-4, Comparative Example 2, Sawacillin Amoxicillin Tablets Reference Preparation (Amoxicillin Tablets Reference Preparation is produced by Astellas Pharma Inc. of Japan, with the trade name Sawacillin® and a drug specification of 0.25 g) in a pH 6.8 dissolution medium are as follows:
实施例1-4、对比例2、Sawacillin阿莫西林片参比制剂的阿莫西林溶出曲线见图3所示。The amoxicillin dissolution curves of Examples 1-4, Comparative Example 2, and Sawacillin Amoxicillin Tablets Reference Preparation are shown in FIG3 .
由富马酸伏诺拉生和阿莫西林的溶出度和溶出曲线结果可以看出,实施例1-4制备的富马酸伏诺拉生制剂与市售规格为20mg的富马酸伏诺拉生片(沃克)和市售规格为0.25g的阿莫西林片(Sawacillin)具有极高的相似度,因此,在药效相当的情况下,使用实施例1-4制备的富马酸伏诺拉生制剂,能够减少服药量和服药次数,对老年患者尤其友好。对比例2中,将富马酸伏诺拉生加入片芯组分,将阿莫西林加入药物层以后,阿莫西林能正常释放,但由于片芯之外的包衣增重过多,导致了富马酸伏诺拉生的溶出速度减慢,所以将阿莫西林添加在药物层中包衣的方法行不通。It can be seen from the dissolution and dissolution curve results of vonoprazan fumarate and amoxicillin that the vonoprazan fumarate preparation prepared in Example 1-4 has a high similarity with the commercially available vonoprazan fumarate tablets (Walker) with a specification of 20 mg and the commercially available amoxicillin tablets (Sawacillin) with a specification of 0.25 g. Therefore, under the condition of equivalent efficacy, the vonoprazan fumarate preparation prepared in Example 1-4 can reduce the dosage and frequency of medication, which is particularly friendly to elderly patients. In Comparative Example 2, after vonoprazan fumarate is added to the tablet core component and amoxicillin is added to the drug layer, amoxicillin can be released normally, but due to the excessive weight gain of the coating outside the tablet core, the dissolution rate of vonoprazan fumarate is slowed down, so the method of adding amoxicillin to the drug layer for coating is not feasible.
3.稳定性检测3. Stability test
对实施例1的制剂进行放置稳定性试验,在25±2℃,60±5%RH下进行加速试验,并分别在加速试验前和加速试验6个月后进行有关物质的检验。The preparation of Example 1 was subjected to a storage stability test, an accelerated test was performed at 25±2°C, 60±5%RH, and related substances were tested before and 6 months after the accelerated test.
色谱条件:用C18色谱柱,以0.025mol/L的磷酸-乙腈-甲醇混合物(14:1:5)为流动相A;以0.025mol/L的磷酸-乙腈混合物(3:7)为流动相B。检测波长230nm,按下表进行梯度洗脱:Chromatographic conditions: Use a C18 column, with a 0.025 mol/L phosphoric acid-acetonitrile-methanol mixture (14:1:5) as mobile phase A; a 0.025 mol/L phosphoric acid-acetonitrile mixture (3:7) as mobile phase B. Detection wavelength 230 nm, gradient elution according to the following table:
富马酸伏诺拉生有关物质稳定性实验结果如下表:The results of the stability test of related substances of vonoprazan fumarate are as follows:
色谱条件:用C18色谱柱,以0.05mol/L磷酸盐缓冲液(0.05mol/L磷酸二氢钾溶液,用2mol/L氢氧化钾溶液调节pH值至5.0)﹣乙腈(99:1)为流动相A;以0.05mol/L磷酸盐缓冲液(pH5.0)﹣乙腈(80:20)为流动相B;检测波长为254nm;柱温为35℃;进样量20μL;进样温度:4℃。按下表进行梯度洗脱:Chromatographic conditions: C18 column, 0.05mol/L phosphate buffer (0.05mol/L potassium dihydrogen phosphate solution, pH adjusted to 5.0 with 2mol/L potassium hydroxide solution)-acetonitrile (99:1) as mobile phase A; 0.05mol/L phosphate buffer (pH5.0)-acetonitrile (80:20) as mobile phase B; detection wavelength 254nm; column temperature 35℃; injection volume 20μL; injection temperature: 4℃. Gradient elution according to the following table:
阿莫西林有关物质稳定性实验结果如下表:The results of the stability test of amoxicillin related substances are as follows:
由稳定性检测结果可以看出,实施例1制得的富马酸伏诺拉生制剂在加速试验6个月后杂质含量变化不大,说明实施例1制得的富马酸伏诺拉生制剂具有优秀的稳定性。It can be seen from the stability test results that the impurity content of the vonoprazan fumarate preparation prepared in Example 1 did not change much after the accelerated test for 6 months, indicating that the vonoprazan fumarate preparation prepared in Example 1 has excellent stability.
除非另有说明,本发明中所采用的百分数均为质量百分数。Unless otherwise specified, all percentages used in the present invention are by mass.
最后应说明的是:以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410675348.4A CN118236338B (en) | 2024-05-29 | 2024-05-29 | Preparation method of voronoi fumarate preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410675348.4A CN118236338B (en) | 2024-05-29 | 2024-05-29 | Preparation method of voronoi fumarate preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN118236338A CN118236338A (en) | 2024-06-25 |
CN118236338B true CN118236338B (en) | 2024-09-17 |
Family
ID=91555109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410675348.4A Active CN118236338B (en) | 2024-05-29 | 2024-05-29 | Preparation method of voronoi fumarate preparation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118236338B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110831579A (en) * | 2017-07-10 | 2020-02-21 | 武田药品工业株式会社 | Formulations comprising vorozan |
CN116966180A (en) * | 2022-11-10 | 2023-10-31 | 山东道合药业有限公司 | Vonoprazan pyroglutamate tablets, injections, and compound preparations |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH12018500236B1 (en) * | 2015-07-30 | 2023-12-06 | Takeda Pharmaceuticals Co | Tablet |
CN114053239A (en) * | 2020-08-01 | 2022-02-18 | 吉林汇康制药有限公司 | Voranolasheng fumarate pharmaceutical composition and preparation method thereof |
CN117503707B (en) * | 2022-08-05 | 2024-08-23 | 哈尔滨市康隆药业有限责任公司 | A taste-masking microsphere and its preparation process and application |
-
2024
- 2024-05-29 CN CN202410675348.4A patent/CN118236338B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110831579A (en) * | 2017-07-10 | 2020-02-21 | 武田药品工业株式会社 | Formulations comprising vorozan |
CN116966180A (en) * | 2022-11-10 | 2023-10-31 | 山东道合药业有限公司 | Vonoprazan pyroglutamate tablets, injections, and compound preparations |
Also Published As
Publication number | Publication date |
---|---|
CN118236338A (en) | 2024-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2011290614B2 (en) | Nalbuphine-based formulations and uses thereof | |
TWI228414B (en) | Pharmaceutical composition comprising carvedilol and hydrochlorothiazide, solid dosage form comprising it, and process for the production of the same | |
JPS6165817A (en) | pellet formulation | |
CN113616624B (en) | Empagliflozin metformin sustained release preparation and preparation method thereof | |
CN117815195B (en) | JAK inhibitor composition and preparation process thereof | |
CN114302712B (en) | Acipimox multi-unit sustained-release pellet tablet and preparation method thereof | |
SK194A3 (en) | Tables of medicines mixtures of colestipol hydrochloride | |
CN115581686B (en) | Preparation method of pregabalin capsule and pregabalin capsule | |
WO2024234555A1 (en) | Dapagliflozin/metformin sustained release tablet, preparation method therefor, and application thereof | |
JP2022534159A (en) | Micronized solid melatonin composition | |
US20050245614A1 (en) | Tranexamic acid formulations | |
WO2023070985A1 (en) | Abidor hydrochloride tablet and preparation method therefor | |
CN102755310B (en) | A kind of composition medicine preparation containing levodopa | |
CN118236338B (en) | Preparation method of voronoi fumarate preparation | |
CN117442577B (en) | Candesartan cilexetil microchip and preparation method and application thereof | |
CN101411702B (en) | Nefopam hydrochloride naproxen sodium compound sustained-release preparation and preparation method thereof | |
CN117838649A (en) | Prednisolone enteric-coated sustained-release tablets and preparation method thereof | |
TWI608849B (en) | High drug load pharmaceutical compositions with controllable release rate and production methods thereof | |
CN103505466B (en) | Solid compound preparation containing metformin hydrochloride and glimepiride and its production and use | |
CN112569190A (en) | Oral administration preparation of pulsatilla chinensis saponin B4 and preparation method thereof | |
CN115124420A (en) | Rhein and matrine co-crystal hydrate and preparation method, composition and use thereof | |
WO2020155098A1 (en) | Pharmaceutical composition for treating diabetes, preparation method therefor, and use thereof | |
CN108186589B (en) | A kind of azelnidipine composition | |
CN110115715A (en) | A kind of composite tablet and preparation method thereof containing Irbesartan | |
CN118787603B (en) | Pioglitazone and enggliflozin compound tablet as well as preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |